Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases

Bibliography

• Sohda T, Meguro K, Kawamatsu Y. Studies on antidiabetic agents. IV. Synthesis and activity of the metabolites of 5-[4-(1-methylcyclohexylmethoxy)benzyl]-2,4-thiazolidinedione (ciglitazone). Chem Pharm Bull 1984;32:2267-78
   PubMed Web of Science ®Google Scholar
• Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992;15:1075-8
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Moore LB, Smith-Oliver TA, et.al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor [gamma] (PPAR [gamma]). J Biol Chem 1995;270:12953-6
   PubMed Web of Science ®Google Scholar
• Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trend Endocrinol. Metab 2000;11:362-8
   PubMed Web of Science ®Google Scholar
• Peraza MA, Burdick AD, Marin HE, et al. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci 2006;90:269-95
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. Treatment issues in Type 2 diabetes. Diabetes Care 2002;25:390-4
   PubMed Web of Science ®Google Scholar
• Rucker C, Scaarsi M, Meringer M. 2D QSAR of PPARγ agonist binding and transactivation. Bioorg Med Chem 2006;14:5178-95
   PubMed Web of Science ®Google Scholar
• Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992;41:393
   PubMed Web of Science ®Google Scholar
• Martin JA, Brooks DA, Prieto L, et al. 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents. Bioorg Med Chem Lett 2005;15(1):51-5
   PubMed Web of Science ®Google Scholar
• Haigh SKB, Allen G, Birrell HC, et al. Non-thiazolidinedione antihyperglycemica agents. Part 3: the effects of stereochemistry on the potency of α-Methoxy-β-phenylpropanpic acids. Bioorg Med Chem 1999;7:821-30
   PubMed Web of Science ®Google Scholar
• Azukizawa S, Kasai M, Takahashi K, et al. Synthesis and biological evaluation of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: a novel series of PPAR gamma agonists. Chem Pharm Bull (Tokyo) 2008;56(3):335-45
   PubMed Web of Science ®Google Scholar
• Liu KG, Lambert MH, Ayscue AH, et al. Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight. Bioorg Med Chem Lett 2001;11(24):3111-13
   PubMed Web of Science ®Google Scholar
• Lu Y, Guo Z, Guo Y, et al. Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists. Biorgan Med Chem Lett 2006;16:915-919L
   PubMed Web of Science ®Google Scholar
• Pirat C, Farce A, Lebegue N, et al. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J Med Chem 2012;55(9):4027-61
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm Res 2001;56:239
   PubMedGoogle Scholar
• Dietz M, Mohr P, Kuhn B, et al. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. Chem Med Chem 2012;7:1101-11
   Google Scholar
• Colca JR, Kletzien RF. What has prevented the expansion of insulin sensitisers? Expert Opin Investig Drugs 2006;15(3):205-10
   PubMed Web of Science ®Google Scholar
• Colca JR. Insulin sensitizers may prevent metabolic inflammation. Biochem Pharmacol 2006;72(2):125-31
   PubMed Web of Science ®Google Scholar
• Winkelmayer WC, Setoguchi S, Levin R, Solomon DK. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone. Therapy Arch Intern Med 2008;168:2368-75
   PubMed Web of Science ®Google Scholar
• Ryder REJ. Pioglitazone: an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimum management of type 2 diabetes. Br. J. Diabetes Vasc Dis 2011;11:113-20
   Google Scholar
• Henry RR, Erikson D, Ciraldi TA. PPAR Agonists and the Future for Insulin Sensitizers. Br. J. Diabetes Vasc Dis 2012;12:206-10
   Google Scholar
• Feinstein DL, Spagnolo A, Akar C, et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 2005;70(2):177-88
   PubMed Web of Science ®Google Scholar
• Dello Russo C, Gavrilyuk V, Weinberg G, et al. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003;278:5828-36
   PubMed Web of Science ®Google Scholar
• Brunmair B, Gras F, Neschen S, et al. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-{gamma}-mediated changes in gene expression. Diabetes 2001;50:2309-15
   PubMed Web of Science ®Google Scholar
• Brunmair B, Staniek K, Gras F, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004;53:1052-9
   PubMed Web of Science ®Google Scholar
• Konrad D, Rudich A, Bilan PJ, et al. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 2005;48:954-66
   PubMed Web of Science ®Google Scholar
• LeBrasseur NK, Kelly M, Tsao T-S, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006;291:E175-81
   PubMed Web of Science ®Google Scholar
• Lessard SJ, Chen Z-P, Watt MJ, et al. Chronic rosiglitazone treatment restores AMPK{alpha}2 activity in insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab 2006;290:E251-7
   PubMed Web of Science ®Google Scholar
• Ye J-M, Dzamko N, Hoy AJ, et al. Rosiglitazone treatment enhances acute AMP-activated protein kinase-mediated muscle and adipose tissue glucose uptake in high-fat-fed rats. Diabetes 2006;55:2797-804
   PubMed Web of Science ®Google Scholar
• Boyle JG, Logan PL, Ewar M-A, et al. Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J Biol Chem 2008;283:11210-17
   PubMed Web of Science ®Google Scholar
• Ceolotton G, Gallo A, Papparella I, et al. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H Oxidase via AMPK-dependent mechanism arterioscler. Thromb. Vasc. Biol 2007;27:2627-33
   PubMed Web of Science ®Google Scholar
• Lombardi A, Cantini G, Piscitelli E, et al.et al. new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-{alpha} and interferon-{gamma} inflammatory effects in human endothelial cells. Arterioscler Thromb Vasc Biol 2008;28:718-24
   PubMed Web of Science ®Google Scholar
• Hardie DG, Sakamoto K. AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology 2006;21:48-60
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Park H, Kaushik VK, et al. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand 2003;178(4):435-42
   PubMedGoogle Scholar
• Colca JR, McDonald WG, Waldon DJ, et al. Identification of a novel mitochondrial protein (‘mitoNEET’) cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 2004;286:252-60
   PubMed Web of Science ®Google Scholar
• Colca JR, McDonald WG, Cavey GS, et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLOS ONE 2013;8:e61551-1-10
   PubMed Web of Science ®Google Scholar
• Colca JR, VanderLugt JT, Adams WJ, et al. Clinical proof of concept with MSDC-0160, a prototype mTOT modulating insulin sensitizer. Clin Pharmaco Thera 2013;93:352-9
   PubMed Web of Science ®Google Scholar
• Chen Z, Vigueira PA, Chambers KT, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor -sparing thiazolidinedione. J Biol Chem 2012;287:23537-48
   PubMed Web of Science ®Google Scholar
• Handy DE, Loscalzo J. Redox regulation of mitochondrial function. Antioxidant and Redox Signaling 2012;16:1323-67
   PubMed Web of Science ®Google Scholar
• McDonald WG, Cole SL, Holewa DD, et al. New insulin sensitizers produce differentiation of brown-like adipose cells from a subcutaneous fat depot and increase secretion of adiponectin in vitro. Diabetologia 2011;54(Suppl 1):S15
   Google Scholar
• Rohatgi N, Aly H, Marshall CA, et al. Novel insulin sensitizer modulates nutrient sensitizing pathways and maintains β-cell phenotype in human islets. PLoS ONE 2013;8:e62012-1-13
   PubMed Web of Science ®Google Scholar